

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	10/741,534
Filing Date	December 19, 2003
First Named Inventor	Alain BARON
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	18528.675

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
EGS	A1	US- 2002/0137666 A1	09-26-2002	Beeley <i>et al.</i>	
	B1	US- 2003/0087820 A1	05-08-2003	Young <i>et al.</i>	
	C1	US- 2003/0220243 A1	11-27-2003	Glaesner <i>et al.</i>	
	D1	US- 5,118,666	06-02-1992	Habener	
	E1	US- 5,120,712	06-09-1992	Habener	
	F1	US- 5,512,549	04-30-1996	Chen <i>et al.</i>	
	G1	US- 5,545,618	08-13-1996	Buckley <i>et al.</i>	
	H1	US- 5,574,008	11-12-1996	Johnson <i>et al.</i>	
	I1	US- 5,670,360	09-23-1997	Thorens	
	J1	US- 5,705,483	01-06-1998	Galloway <i>et al.</i>	
	K1	US- 5,846,747	12-08-1998	Thorens <i>et al.</i>	
	L1	US- 5,981,488	11-9-1999	Hoffmann	
	M1	US- 6,051,689	04-18-2000	Thorens	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
EGS	N1	EP 0 708 179 A2	04-24-1996	Eli Lilly and Company		
	O1	WO 91/11457 A1	08-08-1991	Douglas I. BUCKLEY <i>et al.</i>		
	P1	WO 98/05351 A1	02-12-1998	Amylin Pharmaceuticals, Inc.		
	Q1	WO 98/30231 A1	07-16-1998	Amylin Pharmaceuticals, Inc.		
	R1	WO 99/07404 A1	02-18-1999	Amylin Pharmaceuticals, Inc.		

Examiner
Signature

/Elly Gerald Stoica/

Date
Considered

01/26/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number	10/741,534
Filing Date	December 19, 2003
First Named Inventor	Alain BARON
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	18528.675

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
EGS	A2	US- 6,268,343 B1	07-31-2001	Knudsen <i>et al.</i>	
	B2	US- 6,451,974 B1	09-17-2002	Hansen	
	C2	US- 6,451,987 B1	09-17-2002	Staby	
	D2	US- 6,458,924 B2	10-01-2002	Knudsen <i>et al.</i>	
	E2	US- 6,514,500 B1	02-04-2003	Bridon <i>et al.</i>	
	F2	US- 6,528,486 B1	03-04-2003	Larsen <i>et al.</i>	
	G2	US- 6,569,832 B1	05-27-2003	Knudsen <i>et al.</i>	
	H2	US- 6,593,295 B2	07-15-2003	Bridon <i>et al.</i>	
	I2	US-			
	J2	US-			
	K2	US-			
	L2	US-			
	M2	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number-Kind Code ² (if known)				
EGS	N2	WO 99/25727 A2	05-27-1999	Amylin Pharmaceuticals, Inc.		
	O2	WO 99/25728 A1	05-27-1999	Amylin Pharmaceuticals, Inc.		
	P2	WO 01/98331 A2	12-27-2001	Eli Lilly and Company		
	Q2	WO 02/48192 A2	06-20-2002	Eli Lilly and Company		
	R2					

Examiner
Signature

/Elly Gerald Stoica/

Date
Considered

01/26/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

Application Number	10/741,534
Filing Date	December 19, 2003
First Named Inventor	Alain BARON
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	18528.675

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EGS	A3	Adelhorst <i>et al.</i> , "Structure-Activity Studies of Glucagon-Like Peptide-1," <i>J. Biol. Chem.</i> , 269(9):6275-6278 (1994)	
	B3	Byrne <i>et al.</i> , "Human Studies with Glucagon-Like-Peptide-1: Potential of the Gut Hormone for Clinical Use," <i>Diabet. Med.</i> , 13(10):854-860 (1996) (Abstract)	
	C3	D'Alessio <i>et al.</i> , "Elimination of the Action of Glucagon-Like Peptide 1 Causes and Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons," <i>J. Clin. Invest.</i> , 97(1):133-138 (1996)	
	D3	Eng <i>et al.</i> , "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from <i>Heloderma horridum</i> Venom," <i>J. Biol. Chem.</i> , 265(33):20259-20262 (1990)	
	E3	Eng <i>et al.</i> , "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from <i>Heloderma suspectum</i> Venom," <i>J. Biol. Chem.</i> , 267(11):7402-7405 (1992)	
	F3	Hjorth <i>et al.</i> , "Glucagon and Glucagon-Like Peptide 1: Selective Receptor Recognition via Distinct Peptide Epitopes," <i>J. Biol. Chem.</i> , 269(48):30121-30124 (1994)	
	G3	Holz <i>et al.</i> , "Black Widow Spider Alpha-Latrotoxin: A Presynaptic Neurotoxin that Shares Structural Homology with the Glucagon-Like Peptide-1 Family of Insulin Secretagogic Hormones," <i>Comp. Biochem. Biophysiol.</i> , 121(2):177-184 (1998) (Abstract)	
	H3	Irwin <i>et al.</i> , "The <i>Xenopus</i> Proglucagon Gene Encodes Novel GLP-1-Like Peptides with Insulinotropic Properties," <i>Proc. Natl. Acad. Sci. USA</i> , 94:7915-7920 (1997)	
	I3	Mojsov, "Structural Requirements for Biological Activity of Glucagon-Like Peptide-I," <i>Int. J. Pept. Protein Res.</i> , 40(3-4):333-343 (1992) (Abstract)	
	J3	O'Halloran <i>et al.</i> , "Glucagon-Like Peptide-1 (7-36)-NH ₂ : A Physiological Inhibitor of Gastric Acid Secretion in Man," <i>J. Endocrinol.</i> , 126(1):169-173 (1990) (Abstract)	
↓	K3	Orskov <i>et al.</i> , "Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects are Indistinguishable," <i>Diabetes</i> , 42(5):658-661 (1993) (Abstract)	

Examiner Signature	/Elly Gerald Stoica/	Date Considered	01/26/2007
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

4

Complete if Known

Application Number	10/741,534
Filing Date	December 19, 2003
First Named Inventor	Alain BARON
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	18528.675

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EGS	A4	Raufman <i>et al.</i> , "Truncated Glucagon-Like Peptide-1 Interacts with Exendin Receptors on Dispersed Acini from Guinea Pig Pancreas," <i>J. Biol. Chem.</i> , 267(30):21432-21437 (1992)	
	B4	Ritzel <i>et al.</i> , "A Synthetic Glucagon-Like Peptide-1 Analog with Improved Plasma Stability," <i>J. Endocrinol.</i> , 159:93-102 (1998)	
	C4	Schjoldager <i>et al.</i> , "GLP-1 (Glucagon-Like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans," <i>Dig. Dis. Sci.</i> , 34(5):703-708 (1989) (Abstract)	
	D4	Wettergren <i>et al.</i> , "Truncated GLP-1 (Proglucagon 78-107-amide) Inhibits Gastric and Pancreatic Functions in Man," <i>Dig. Dis. Sci.</i> , 38(4):665-673 (1993) (Abstract)	
	E4	Willms <i>et al.</i> , "Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients," <i>J. Clin. Endocrinol. Metab.</i> , 81(1):327-332 (1996) (Abstract)	
	F4		
	G4		
	H4		
	I4		
	J4		
	K4		

Examiner
Signature

/Elly Gerald Stoica/

Date
Considered

01/26/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/741,534
Filing Date	December 19, 2003
First Named Inventor	Alain BARON et al.
Art Unit	1614
Examiner Name	to be assigned
Attorney Docket Number	0218-UTL-9

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Elly Gerald Stoica/	Date Considered	01/22/2007
-----------------------	----------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Application Number	10/741,534
Filing Date	December 19, 2003
First Named Inventor	Alain BARON
Art Unit	1647
Examiner Name	To Be Assigned
Attorney Docket Number	18528.675/0218-UTL-9

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

/Elly Gerald Stoica/


Date	
Considered	

01/22/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/741,534
Filing Date	December 19, 2003
First Named Inventor	Alain BARON
Art Unit	1647
Examiner Name	To Be Assigned
Attorney Docket Number	18528.675/0218-UTL-0

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EGS	C1	International Search Report from International Application No. PCT/US2003/040713 (WO 2004/056317)	

Examiner Signature	/Elly Gerald Stoica/	Date Considered	01/22/2007
-----------------------	----------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.